E
Edgar L. Milford
Researcher at Brigham and Women's Hospital
Publications - 225
Citations - 18072
Edgar L. Milford is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Transplantation & Antigen. The author has an hindex of 54, co-authored 223 publications receiving 16954 citations. Previous affiliations of Edgar L. Milford include Cornell University & University of Utah.
Papers
More filters
Journal ArticleDOI
Presensitization and the renal allograft recipient.
TL;DR: The inability to accurately predict negative crossmatches, and the possible adverse effect of positive historical crossMatches on graft survival, represent potential obstacles to a goal of national organ sharing.
A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.
David R. Snydman,Barbara G. Werner,Nicholas L. Tilney,Robert L. Kirkman,Edgar L. Milford,Cho Si,Bush Hl,Andrew S. Levey,Terry B. Strom,Charles B. Carpenter +9 more
Journal ArticleDOI
Transmission of Hepatitis C Virus by Organ Transplantation
Journal ArticleDOI
Effects of BWH-4 anti-CD4 monoclonal antibody on rat vascularized cardiac allografts before and after engraftment.
Mohamed H. Sayegh,T. Sablinski,Kazuo Tanaka,Jean P. Kut,Cheng A. Kwok,Nicholas L. Tilney,Jerzy W. Kupiec-Weglinski,Edgar L. Milford +7 more
TL;DR: It is concluded that the anti-CD4 mAb, BWH-4, prevents acute rejection of vascularized heterotopic rat cardiac allografts; this effect is mediated by depletion of the CD4+ T cell subset, suppression of alloantibody production, and inhibition of lymphocyte-mediated cytotoxicity.
Journal Article
Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation.
Charles B. Carpenter,Robert L. Kirkman,Michael E. Shapiro,Edgar L. Milford,Tiney Nl,Waldmann Ta,C. E. Zimmerman,Ramos El,Terry B. Strom +8 more
TL;DR: The effect of anti-Tac seems, therefore, to be limited to inhibition of IL-2-mediated T-cell growth during the period of administration, with recovery after a few days' lag period.